| P/E (FY) | 9.9 | Sales (TTM) | $720.5M |
| Earnings (TTM) | $79.2M | ROE | — |
| Net Margin | 13.63% | ROIC | 9.90% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | 5.27% | Sales Growth 3Y | 12.99% |
Amphastar Pharmaceuticals, Inc. is a bio-pharmaceutical company that develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. Products include BAQSIMI nasal spray for severe hypoglycemia, Primatene MIST for mild intermittent asthma, glucagon injection kits, Enoxaparin, REXTOVY and Naloxone for opioid overdose, Cortrosyn for adrenocortical insufficiency screening, Amphadase, and epinephrine and lidocaine injections.
| Market Cap | $888.5M | Trading Days | 3038 |
| 52W High | 31.26 |
| 52W Low | 16.64 |
| % Off High | −35.54% |
| YTD | −24.76% | 1Y | −9.40% |
| 3Y | −66.87% | 5Y | −3.59% |
| 10Y | 23.85% | Since incept. (ann.) | 7.14% |
Pharmaceutical Products 100%
| Ann. Volatility (1Y) | 55.60% | Ann. Volatility (3Y) | 46.58% |
| Sharpe (1Y) | 0.11 | Sharpe (3Y) | −0.55 |
| Max Drawdown (1Y) | −45.25% | Max Drawdown (3Y) | −74.05% |
| Beta (3Y, vs SPY) | 0.98 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ABUS | Arbutus Biopharma Corp | $871.1M | — |
| TBPH | Theravance Biopharma, Inc. | $870.7M | 8.2 |
| JANX | Janux Therapeutics, Inc. | $914.8M | — |
| PHAT | Phathom Pharmaceuticals, Inc. | $930.0M | — |
| GERN | GERON CORP | $930.2M | — |
| KURA | Kura Oncology, Inc. | $826.5M | — |
| CMMB | Chemomab Therapeutics Ltd. | $822.8M | 79.4 |
| ANRO | Alto Neuroscience, Inc. | $962.3M | — |
| ESPR | Esperion Therapeutics, Inc. | $818.6M | — |
| OMER | OMEROS CORP | $816.4M | — |
| JBIO | Jade Biosciences, Inc. | $972.4M |
| BIOA | BioAge Labs, Inc. | $974.4M | — |